Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids,
| Current Price | ₹2,022.15 |
|---|---|
| Market Cap | ₹1,720 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 29.9 |
| Return on Equity | 16.55% |
| 52-Week Range | ₹1,239.30 – ₹2,350.00 |
| Beta (1Y) | -0.05 |
| Dividend Yield | 0.54% |
1. Poultry Healthcare-61.9% 2. Animal Healthcare-38.1%
Hester Biosciences Ltd is trading at ₹2,022.15, with a market capitalisation of ₹1,720 Cr.
Hester Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Hester Biosciences Ltd has a P/E of 29.9 and a return on equity of 16.55%.